公开(公告)号：US11999973B2

公开(公告)日：2024-06-04

申请号：US16604194

申请日：2018-04-10

Applicant: EpicentRx, Inc.

Inventor： Tony R. Reid ,  Bryan T. Oronsky ,  Christopher Larson

IPC: C12N7/00

CPC classification number: C12N7/00 ,  C12N2710/10321 ,  C12N2710/10322 ,  C12N2710/10332 ,  C12N2710/10352

Abstract: The invention relates to a method for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

公开(公告)号：US20200078415A1

公开(公告)日：2020-03-12

申请号：US16604675

申请日：2018-04-12

Applicant: EpicentRx, Inc.

Inventor： Tony R. Reid ,  Christopher Larson ,  Bryan T. Oronsky

IPC: A61K35/74 ,  C12N9/64 ,  C12N15/86

Abstract: The invention relates to a recombinant adenovirus comprising two or more therapeutic transgenes, e.g., two components of a heterodimeric cytokine, separated by a cleavable linker.

公开(公告)号：US12291726B2

公开(公告)日：2025-05-06

申请号：US18649467

申请日：2024-04-29

Applicant: EpicentRx, Inc.

Inventor： Tony R. Reid ,  Bryan T. Oronsky ,  Christopher Larson

IPC: C12N5/09 ,  C12N7/00

Abstract: The present disclosure relates to compositions and methods for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

公开(公告)号：US11253608B2

公开(公告)日：2022-02-22

申请号：US15991745

申请日：2018-05-29

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Bryan Oronsky ,  Tony R. Reid

IPC: C12N15/85 ,  A61K47/68 ,  A61P35/00 ,  A61K47/69 ,  C12N7/04 ,  A61K48/00 ,  C12N15/62 ,  C12N7/02 ,  C12N15/86

Abstract: Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.

公开(公告)号：US10906957B2

公开(公告)日：2021-02-02

申请号：US15717199

申请日：2017-09-27

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC: C07K14/71 ,  C12N7/00 ,  A61P35/00 ,  C07K16/00 ,  C12N15/86 ,  A61K48/00 ,  A61K35/768 ,  A61K38/00

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20190352616A1

公开(公告)日：2019-11-21

申请号：US16482055

申请日：2018-01-30

Applicant: EpicentRx, Inc.

Inventor： Tony R. Reid ,  Bryan T. Oronsky ,  Christopher Larson

IPC: C12N7/00 ,  A61K35/761 ,  C07K14/705 ,  A61P35/00

Abstract: The invention provides a recombinant adenovirus comprising two (or more) therapeutic transgenes, e.g., CD80 and CD137L. The transgenes are preferably inserted into an E1b-19K insertion site and/or an E3 insertion site.